{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:53:05Z","timestamp":1781535185922,"version":"3.54.5"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["C2025201053"],"award-info":[{"award-number":["C2025201053"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-026-06132-1","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:44:02Z","timestamp":1777409042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases"],"prefix":"10.1007","volume":"83","author":[{"given":"Jie","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiya","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8797-1322","authenticated-orcid":false,"given":"Chunfu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"6132_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong G, Chang X, Xie W, Zhou X (2024) Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther 9:308. https:\/\/doi.org\/10.1038\/s41392-024-02004-x","journal-title":"Signal Transduct Target Ther"},{"key":"6132_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao J, Zhong K, Tong A, Jia D (2022) Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther 7:113. https:\/\/doi.org\/10.1038\/s41392-022-00966-4","journal-title":"Signal Transduct Target Ther"},{"key":"6132_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104178","volume":"29","author":"D Pliatsika","year":"2024","unstructured":"Pliatsika D, Blatter C, Riedl R (2024) Targeted protein degradation: current molecular targets, localization, and strategies. Drug Discov Today 29:104178. https:\/\/doi.org\/10.1016\/j.drudis.2024.104178","journal-title":"Drug Discov Today"},{"key":"6132_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.tips.2020.02.006","volume":"41","author":"M Kostic","year":"2020","unstructured":"Kostic M, Jones LH (2020) Critical assessment of targeted protein degradation as a research tool and pharmacological modality. Trends Pharmacol Sci 41:305\u2013317. https:\/\/doi.org\/10.1016\/j.tips.2020.02.006","journal-title":"Trends Pharmacol Sci"},{"key":"6132_CR5","doi-asserted-by":"publisher","first-page":"8832","DOI":"10.1039\/d2cs00624c","volume":"51","author":"Y Ding","year":"2022","unstructured":"Ding Y, Xing D, Fei Y, Lu B (2022) Emerging degrader technologies engaging lysosomal pathways. Chem Soc Rev 51:8832\u20138876. https:\/\/doi.org\/10.1039\/d2cs00624c","journal-title":"Chem Soc Rev"},{"key":"6132_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/molecules31010033","author":"RK Acharyya","year":"2025","unstructured":"Acharyya RK et al (2025) An update on clinically advanced PROTAC degraders and their synthesis. Molecules. https:\/\/doi.org\/10.3390\/molecules31010033","journal-title":"Molecules"},{"key":"6132_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2023.100413","volume":"4","author":"J Li","year":"2023","unstructured":"Li J, Chen X, Lu A, Liang C (2023) Targeted protein degradation in cancers: orthodox PROTACs and beyond. Innovation Camb 4:100413. https:\/\/doi.org\/10.1016\/j.xinn.2023.100413","journal-title":"Innovation Camb"},{"key":"6132_CR8","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s00204-024-03930-z","volume":"99","author":"MD Collins","year":"2025","unstructured":"Collins MD, Scott WJ (2025) Thalidomide-induced limb malformations: an update and reevaluation. Arch Toxicol 99:1643\u20131747. https:\/\/doi.org\/10.1007\/s00204-024-03930-z","journal-title":"Arch Toxicol"},{"key":"6132_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09994-w","author":"VN Dippon","year":"2026","unstructured":"Dippon VN et al (2026) Identification of an allosteric site on the E3 ligase adapter cereblon. Nature. https:\/\/doi.org\/10.1038\/s41586-025-09994-w","journal-title":"Nature"},{"key":"6132_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cmet.2025.11.013","volume":"38","author":"G Li","year":"2026","unstructured":"Li G et al (2026) Mitochondrial VHL rewires cell metabolism in hypoxia. Cell Metab 38:174-191 e177. https:\/\/doi.org\/10.1016\/j.cmet.2025.11.013","journal-title":"Cell Metab"},{"key":"6132_CR11","doi-asserted-by":"publisher","unstructured":"Kalathiya U, Marek-Trzonkowska N, Padariya M (2026) Characterizing p53 structural insights of variants in vertebrates that interfere its regulatory interaction with Mdm2. Dev Comp Immunol 105554. https:\/\/doi.org\/10.1016\/j.dci.2026.105554","DOI":"10.1016\/j.dci.2026.105554"},{"key":"6132_CR12","doi-asserted-by":"publisher","unstructured":"Niebel B, Chen W, Mukai K, Henry C (2026) LYTACs and other extracellular targeted protein degradation tacnologies: guiding principles and potential clinical prospects. Drug Discov Today 104601. https:\/\/doi.org\/10.1016\/j.drudis.2026.104601","DOI":"10.1016\/j.drudis.2026.104601"},{"key":"6132_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107466","volume":"149","author":"J Zhang","year":"2024","unstructured":"Zhang J, Pan X, Ji W, Zhou J (2024) Autophagy mediated targeting degradation, a promising strategy in drug development. Bioorg Chem 149:107466. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107466","journal-title":"Bioorg Chem"},{"key":"6132_CR14","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1021\/ja039025z","volume":"126","author":"JS Schneekloth Jr.","year":"2004","unstructured":"Schneekloth JS Jr. et al (2004) Chemical genetic control of protein levels: selective in vivo targeted degradation. J Am Chem Soc 126:3748\u20133754. https:\/\/doi.org\/10.1021\/ja039025z","journal-title":"J Am Chem Soc"},{"key":"6132_CR15","doi-asserted-by":"crossref","unstructured":"Cruz Walma DA, Chen Z, Bullock AN, Yamada KM (2022) Ubiquitin ligases: guardians of mammalian development. 23:350\u2013367","DOI":"10.1038\/s41580-021-00448-5"},{"key":"6132_CR16","doi-asserted-by":"crossref","unstructured":"Tsai JM, Nowak RP, Ebert BL, Fischer ESJ (2024) Targeted protein degradation: from mechanisms to clinic. 25:740\u2013757","DOI":"10.1038\/s41580-024-00729-9"},{"key":"6132_CR17","doi-asserted-by":"crossref","unstructured":"Min J et al (2021) Phenyl-Glutarimides: alternative cereblon binders for the design of protacs. 60:26663\u201326670","DOI":"10.1002\/anie.202108848"},{"key":"6132_CR18","doi-asserted-by":"crossref","unstructured":"Wells JA, Kumru KJ (2024) Extracellular targeted protein degradation: an emerging modality for drug discovery. 23:126\u2013140","DOI":"10.1038\/s41573-023-00833-z"},{"key":"6132_CR19","doi-asserted-by":"crossref","unstructured":"Zhao L et al (2022) Targeted protein degradation: mechanisms, strategies and application. 7:113","DOI":"10.1038\/s41392-022-00966-4"},{"key":"6132_CR20","doi-asserted-by":"crossref","unstructured":"Yang J, Bai R, Chen B, Suo ZJ (2020) Hydrogel adhesion: a supramolecular synergy of chemistry, topology, and mechanics. 30:1901693","DOI":"10.1002\/adfm.201901693"},{"key":"6132_CR21","doi-asserted-by":"crossref","unstructured":"Domostegui A, Nieto-Barrado L, Perez-Lopez C, Mayor-Ruiz CJ (2022) Chasing molecular glue degraders: screening approaches. 51:5498\u20135517","DOI":"10.1039\/D2CS00197G"},{"key":"6132_CR22","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","volume":"103","author":"R LeBlanc","year":"2004","unstructured":"LeBlanc R (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103:1787\u20131790","journal-title":"Blood"},{"key":"6132_CR23","doi-asserted-by":"crossref","unstructured":"Franks ME, Macpherson GR, Figg WD (2004) Thalidomide 363:1802\u20131811","DOI":"10.1016\/S0140-6736(04)16308-3"},{"key":"6132_CR24","doi-asserted-by":"crossref","unstructured":"Chanan-Khan AA, Cheson BDJ (2008) Lenalidomide for the treatment of B-cell malignancies. 26:1544\u20131552","DOI":"10.1200\/JCO.2007.14.5367"},{"key":"6132_CR25","doi-asserted-by":"crossref","unstructured":"Tefferi A et al (2009) Pomalidomide is active in the treatment of anemia associated with myelofibrosis. 27:4563\u20134569","DOI":"10.1200\/JCO.2008.21.7356"},{"key":"6132_CR26","doi-asserted-by":"crossref","unstructured":"Vargesson NJB, D. (2015) Thalidomide-induced teratogenesis: history and mechanisms. 105:140\u2013156","DOI":"10.1002\/bdrc.21096"},{"key":"6132_CR27","doi-asserted-by":"crossref","unstructured":"Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its imid derivatives as anticancer agents. 4:314\u2013322","DOI":"10.1038\/nrc1323"},{"key":"6132_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-2-36","volume":"2","author":"V Kotla","year":"2009","unstructured":"Kotla V (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:1\u201310","journal-title":"J Hematol Oncol"},{"key":"6132_CR29","doi-asserted-by":"crossref","unstructured":"Chrisochoidou Y et al (2025) Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel CRBN binding agents in myeloma","DOI":"10.1182\/blood.2024025861"},{"key":"6132_CR30","doi-asserted-by":"crossref","unstructured":"Dong G, Ding Y, He S, Sheng CJ (2021) Molecular glues for targeted protein degradation: from serendipity to rational discovery. 64:10606\u201310620","DOI":"10.1021\/acs.jmedchem.1c00895"},{"key":"6132_CR31","doi-asserted-by":"crossref","unstructured":"Kr\u00f6nke J et al (2015) Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in Del (5q) MDS. 523:183\u2013188","DOI":"10.1038\/nature14610"},{"key":"6132_CR32","doi-asserted-by":"crossref","unstructured":"Matyskiela ME et al (2016) A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. 535:252\u2013257","DOI":"10.1038\/nature18611"},{"key":"6132_CR33","doi-asserted-by":"crossref","unstructured":"Hansen JD et al (2021) CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia. 64:1835\u20131843","DOI":"10.1021\/acs.jmedchem.0c01489"},{"key":"6132_CR34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2201208119","volume":"119","author":"J Fang","year":"2022","unstructured":"Fang J et al (2022) Proximity interactome analysis of Lassa polymerase reveals eRF3a\/GSPT1 as a druggable target for host-directed antivirals. Proc Natl Acad Sci U S A 119:e2201208119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6132_CR35","doi-asserted-by":"crossref","unstructured":"Gavory G et al (2023) Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction. 83:3449\u20133449","DOI":"10.1158\/1538-7445.AM2023-3449"},{"key":"6132_CR36","doi-asserted-by":"publisher","DOI":"10.7150\/thno.62686","volume":"11","author":"J Lin","year":"2021","unstructured":"Lin J et al (2021) Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics 11:8337","journal-title":"Theranostics"},{"key":"6132_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","volume":"584","author":"SM Banik","year":"2020","unstructured":"Banik SM et al (2020) Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584:291\u2013297","journal-title":"Nature"},{"key":"6132_CR38","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.cell.2017.12.032","volume":"172","author":"S Markmiller","year":"2018","unstructured":"Markmiller S et al (2018) Context-dependent and disease-specific diversity in protein interactions within stress granules. Cell 172:590-604. e513","journal-title":"Cell"},{"key":"6132_CR39","doi-asserted-by":"crossref","unstructured":"Shao J et al (2021) Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O\u2019PROTAC): effective targeting of LEF1 and ERG. 8:2102555","DOI":"10.1002\/advs.202102555"},{"key":"6132_CR40","doi-asserted-by":"crossref","unstructured":"Zhou Y, Teng P, Montgomery NT, Li X, Tang WJ (2021) Development of triantennary N-acetylgalactosamine conjugates as degraders for extracellular proteins. 7:499\u2013506","DOI":"10.1021\/acscentsci.1c00146"},{"key":"6132_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/s0092-8674(88)80026-6","volume":"52","author":"G Griffiths","year":"1988","unstructured":"Griffiths G, Hoflack B, Simons K, Mellman I, Kornfeld S (1988) The mannose 6-phosphate receptor and the biogenesis of lysosomes. Cell 52:329\u2013341. https:\/\/doi.org\/10.1016\/s0092-8674(88)80026-6","journal-title":"Cell"},{"key":"6132_CR42","doi-asserted-by":"crossref","unstructured":"Li Y-y, Yang Y, Zhang R-s, Ge R-x, Xie S (2025) Targeted degradation of membrane and extracellular proteins with LYTACs. 46:1\u20137","DOI":"10.1038\/s41401-024-01364-y"},{"key":"6132_CR43","doi-asserted-by":"crossref","unstructured":"Song J et al (2023) Targeted protein degradation in drug development: recent advances and future challenges. 261:115839","DOI":"10.1016\/j.ejmech.2023.115839"},{"key":"6132_CR44","doi-asserted-by":"crossref","unstructured":"Ou L, Setegne MT, Elliot J, Shen F, Dassama LM (2025) Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics","DOI":"10.1021\/acs.chemrev.4c00595"},{"key":"6132_CR45","doi-asserted-by":"crossref","unstructured":"Raffeiner M, Zhu S, Gonz\u00e1lez-Fuente M, \u00dcst\u00fcn S (2023) Interplay between autophagy and proteasome during protein turnover. 28:698\u2013714","DOI":"10.1016\/j.tplants.2023.01.013"},{"key":"6132_CR46","doi-asserted-by":"crossref","unstructured":"Zhang J, Pan X, Ji W, Zhou JJ (2024) Autophagy mediated targeting degradation, a promising strategy in drug development. 107466","DOI":"10.1016\/j.bioorg.2024.107466"},{"key":"6132_CR47","doi-asserted-by":"crossref","unstructured":"Takahashi D et al (2019) AUTACs: cargo-specific degraders using selective autophagy. 76:797\u2013810","DOI":"10.1016\/j.molcel.2019.09.009"},{"key":"6132_CR48","doi-asserted-by":"crossref","unstructured":"Takahashi D et al (2023) Second-generation AUTACs for targeted autophagic degradation. 66:12342\u201312372","DOI":"10.1021\/acs.jmedchem.3c00861"},{"key":"6132_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01811-z","volume":"10","author":"C Luo","year":"2024","unstructured":"Luo C (2024) LncRNA HOTAIR regulates autophagy and proliferation mechanisms in premature ovarian insufficiency through the miR-148b-3p\/ATG14 axis. Cell Death Discov 10:44","journal-title":"Cell Death Discov"},{"key":"6132_CR50","doi-asserted-by":"crossref","unstructured":"Zhang H, An P, Fei Y, Lu BJ (2021) Modeling the degradation effects of autophagosome tethering compounds. 37:255\u2013260","DOI":"10.1007\/s12264-020-00574-8"},{"key":"6132_CR51","doi-asserted-by":"crossref","unstructured":"Thorne RG, Frey WH (2001) Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. 40:907\u2013946","DOI":"10.2165\/00003088-200140120-00003"},{"key":"6132_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2024.106001","volume":"104","author":"K Mittal","year":"2025","unstructured":"Mittal K (2025) TPD-seq: a high throughput RNA-seq method to derive transcriptomic points of departure from cell lines. Toxicol In Vitro 104:106001","journal-title":"Toxicol In Vitro"},{"key":"6132_CR53","first-page":"777","volume":"136","author":"TA Cooper","year":"2009","unstructured":"Cooper TA, Wan L, Dreyfuss G (2009) J C RNA Disease 136:777\u2013793","journal-title":"J C RNA Disease"},{"key":"6132_CR54","doi-asserted-by":"crossref","unstructured":"Bonet-Aleta J, Maehara T, Craig BA, Bernardes GJ (2024) Small molecule RNA degraders. 63:e202412925","DOI":"10.1002\/anie.202412925"},{"key":"6132_CR55","doi-asserted-by":"crossref","unstructured":"Burke JM, Moon SL, Matheny T, Parker R (2019) RNase L reprograms translation by widespread mRNA turnover escaped by antiviral mRNAs. 75:1203\u20131217 e1205","DOI":"10.1016\/j.molcel.2019.07.029"},{"key":"6132_CR56","doi-asserted-by":"crossref","unstructured":"Bhattacharjee S, Roche B, Martienssen RA (2019) RNA-induced initiation of transcriptional Silencing (RITS) complex structure and function. 16:1133\u20131146","DOI":"10.1080\/15476286.2019.1621624"},{"key":"6132_CR57","doi-asserted-by":"crossref","unstructured":"Mikutis S, Bernardes GJJC (2024) Technologies for targeted RNA degradation and induced RNA decay. 124:13301\u201313330","DOI":"10.1021\/acs.chemrev.4c00472"},{"key":"6132_CR58","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.4155\/fmc-2021-0096","volume":"13","author":"A Singh","year":"2021","unstructured":"Singh A (2021) The role of microRNA-21 in the onset and progression of cancer. Future Med Chem 13:1885\u20131906","journal-title":"Future Med Chem"},{"key":"6132_CR59","doi-asserted-by":"crossref","unstructured":"Cao C et al (2021) The architecture of the SARS-CoV-2 RNA genome inside virion. 12:3917","DOI":"10.1038\/s41467-021-22785-x"},{"key":"6132_CR60","doi-asserted-by":"crossref","unstructured":"Nakamori MJN, Neuroscience C (2024) Expanded-repeat\u2010RNA\u2010mediated disease mechanisms in myotonic dystrophy. 12:16\u201323","DOI":"10.1111\/ncn3.12687"},{"key":"6132_CR61","first-page":"15483","volume":"63","author":"CS Kounde","year":"2020","unstructured":"Kounde CS, Tate EWJ (2020) Photoactive bifunctional degraders: precision tools to regulate protein stability: Miniperspective. J. o. M. C. 63:15483\u201315493","journal-title":"J. o. M. C."},{"key":"6132_CR62","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1039\/D2CS00148A","volume":"51","author":"I Sosi\u010d","year":"2022","unstructured":"Sosi\u010d I, Bricelj A, Steinebach C (2022) E3 ligase ligand chemistries: from building blocks to protein degraders. Chem Soc Rev 51:3487\u20133534","journal-title":"Chem Soc Rev"},{"key":"6132_CR63","first-page":"140","volume":"66","author":"KB Hong","year":"2022","unstructured":"Hong KB, An HJ (2022) Degrader\u2013antibody conjugates: emerging new modality. J O M C 66:140\u2013148","journal-title":"J O M C"},{"key":"6132_CR64","doi-asserted-by":"crossref","unstructured":"He Q et al (2023) Hydrophobic tag-based protein degradation: Development, opportunity and challenge. 260:115741","DOI":"10.1016\/j.ejmech.2023.115741"},{"key":"6132_CR65","doi-asserted-by":"crossref","unstructured":"Yang Z, Pang Q, Zhou J, Xuan C, Xie S (2023) Leveraging aptamers for targeted protein degradation. 44:776\u2013785","DOI":"10.1016\/j.tips.2023.05.008"},{"key":"6132_CR66","doi-asserted-by":"crossref","unstructured":"Xu Y et al (2023) Aptamer-based RNA-PROTAC 86:117299","DOI":"10.1016\/j.bmc.2023.117299"},{"key":"6132_CR67","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.1021\/acs.jmedchem.2c00397","volume":"65","author":"AJ Gopalsamy","year":"2022","unstructured":"Gopalsamy AJ (2022) Selectivity through targeted protein degradation (TPD) miniperspective. J Med Chem 65:8113\u20138126","journal-title":"J Med Chem"},{"key":"6132_CR68","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s13346-024-01754-z","volume":"15","author":"A Vikal","year":"2025","unstructured":"Vikal A et al (2025) Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions. Drug Deliv Transl Res 15:1801\u20131827. https:\/\/doi.org\/10.1007\/s13346-024-01754-z","journal-title":"Drug Deliv Transl Res"},{"key":"6132_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y (2022) Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther 7:329","journal-title":"Signal Transduct Target Ther"},{"key":"6132_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107234","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Ming A, Wang J, Chen W, Fang Z (2024) PROTACs targeting androgen receptor signaling: potential therapeutic agents for castration-resistant prostate cancer. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2024.107234","journal-title":"Pharmacol Res"},{"key":"6132_CR71","doi-asserted-by":"crossref","unstructured":"Vetma V, O\u2019Connor S, Ciulli AJ (2024) Development of PROTAC degrader drugs for cancer. 9","DOI":"10.1146\/annurev-cancerbio-061824-105806"},{"key":"6132_CR72","doi-asserted-by":"crossref","unstructured":"Lu Y, Liu WJ (2020) Selective Estrogen receptor degraders (SERDs): a promising strategy for Estrogen receptor positive endocrine-resistant breast cancer. 63:15094\u201315114","DOI":"10.1021\/acs.jmedchem.0c00913"},{"key":"6132_CR73","doi-asserted-by":"crossref","unstructured":"Rej RK et al (2024) Discovery of ERD-12310A as an exceptionally potent and orally efficacious PROTAC degrader of Estrogen receptor \u03b1 (ER\u03b1). 67:20933\u201320965","DOI":"10.1021\/acs.jmedchem.4c01401"},{"key":"6132_CR74","first-page":"11384","volume":"25","author":"R Masnikosa","year":"2024","unstructured":"Masnikosa R, Cvetkovi\u0107 Z, Piri\u0107 D, J. I. (2024) J. o. M. S. Tumor biology hides novel therapeutic approaches to diffuse large B-Cell lymphoma. Narrative Rev 25:11384","journal-title":"Narrative Rev"},{"key":"6132_CR75","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1021\/acs.bioconjchem.4c00253","volume":"35","author":"R Kamaraj","year":"2024","unstructured":"Kamaraj R (2024) Targeted protein degradation (TPD) for immunotherapy: understanding proteolysis targeting chimera-driven ubiquitin-proteasome interactions. Bioconjug Chem 35:1089\u20131115","journal-title":"Bioconjug Chem"},{"key":"6132_CR76","doi-asserted-by":"crossref","unstructured":"Noviski MA et al (2022) Concurrent degradation of BTK and imid neosubstrates by NX-2127 enhances multiple mechanisms of tumor killing. 82:1126\u20131126","DOI":"10.1158\/1538-7445.AM2022-1126"},{"key":"6132_CR77","doi-asserted-by":"crossref","unstructured":"Fuchs OJB (2023) Targeting cereblon in hematologic malignancies. 57:100994","DOI":"10.1016\/j.blre.2022.100994"},{"key":"6132_CR78","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1182\/blood-2023-178813","volume":"142","author":"W Zhe","year":"2023","unstructured":"Zhe W (2023) Targeting BCL-XL with a novel VHL-based BCL-XL degrader DT-2216 in pre-clinical JAK2-Mutant AML post-MPN models. Blood 142:4154","journal-title":"Blood"},{"key":"6132_CR79","doi-asserted-by":"crossref","unstructured":"Ishida T, Ciulli AJSD (2021) E3 ligase ligands for PROTACs: how they were found and how to discover new ones. 26:484\u2013502","DOI":"10.1177\/2472555220965528"},{"key":"6132_CR80","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/med.21488","volume":"38","author":"X Lu","year":"2018","unstructured":"Lu X (2018) Targeting EGFRL858R\/T790M and EGFRL858R\/T790M\/C797S resistance mutations in NSCLC: current developments in medicinal chemistry. Med Res Rev 38:1550\u20131581","journal-title":"Med Res Rev"},{"key":"6132_CR81","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jtho.2018.05.027","volume":"13","author":"AB Schrock","year":"2018","unstructured":"Schrock AB (2018) Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors. J Thorac Oncol 13:1312\u20131323","journal-title":"J Thorac Oncol"},{"key":"6132_CR82","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","volume":"25","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam F (2019) Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res 25:2033\u20132041","journal-title":"Clin Cancer Res"},{"key":"6132_CR83","doi-asserted-by":"crossref","unstructured":"Fassl A, Geng Y, Sicinski PJS (2022) CDK4 and CDK6 kinases: From basic science to cancer therapy. 375:eabc1495","DOI":"10.1126\/science.abc1495"},{"key":"6132_CR84","doi-asserted-by":"crossref","unstructured":"Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis","DOI":"10.1371\/journal.pone.0047054"},{"key":"6132_CR85","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41375-018-0044-x","volume":"32","author":"X Zhang","year":"2018","unstructured":"Zhang X (2018) Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32:2224\u20132239","journal-title":"Leukemia"},{"key":"6132_CR86","doi-asserted-by":"crossref","unstructured":"Liang Y, Tian J, Wu TJ (2021) BRD4 in physiology and pathology:\u2018\u2018BET\u2019\u2019on its partners. 43:2100180","DOI":"10.1002\/bies.202100180"},{"key":"6132_CR87","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbcan.2012.10.002","volume":"1835","author":"A Subramaniam","year":"2013","unstructured":"Subramaniam A (2013) Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1835:46\u201360","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"6132_CR88","doi-asserted-by":"crossref","unstructured":"Kim DJ, Chan KS, Sano S, DiGiovanni J (2007) Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. 46:725\u2013731","DOI":"10.1002\/mc.20342"},{"key":"6132_CR89","doi-asserted-by":"crossref","unstructured":"Huang L, Guo Z, Wang F, Fu L (2021) KRAS mutation: from undruggable to druggable in cancer. 6:386","DOI":"10.1038\/s41392-021-00780-4"},{"key":"6132_CR90","doi-asserted-by":"crossref","unstructured":"Gandhi J et al (2019) Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics. 30:339\u2013358","DOI":"10.1515\/revneuro-2016-0035"},{"key":"6132_CR91","doi-asserted-by":"crossref","unstructured":"Espargar\u00f3 A, Sabate RJ (2024) Phosphorylation-driven aggregative proteins in neurodegenerative diseases: implications and therapeutics. 19:966\u2013968","DOI":"10.4103\/1673-5374.382250"},{"key":"6132_CR92","doi-asserted-by":"crossref","unstructured":"Kong D, Meng L, Lin P, Wu G (2025) Advancements in PROTAC-based therapies for neurodegenerative diseases. 1\u201315","DOI":"10.1080\/17568919.2025.2463310"},{"key":"6132_CR93","doi-asserted-by":"crossref","unstructured":"Podvin S, Reardon HT, Yin K, Mosier C, Hook VJ (2019) Multiple clinical features of huntington\u2019s disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration. 266:551\u2013564","DOI":"10.1007\/s00415-018-8940-6"},{"key":"6132_CR94","doi-asserted-by":"crossref","unstructured":"Tsekrekou M, Giannakou M, Papanikolopoulou K, Skretas GJ (2024) Protein aggregation and therapeutic strategies in SOD1-and TDP-43-linked ALS. 11:1383453","DOI":"10.3389\/fmolb.2024.1383453"},{"key":"6132_CR95","doi-asserted-by":"publisher","DOI":"10.7150\/thno.69682","volume":"12","author":"DH Upton","year":"2022","unstructured":"Upton DH (2022) Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy. Theranostics 12:4734","journal-title":"Theranostics"},{"key":"6132_CR96","doi-asserted-by":"crossref","unstructured":"Kalliolias GD, Basdra EK, Papavassiliou AG (2024) Targeting TLR signaling cascades in systemic lupus erythematosus and rheumatoid arthritis: an update. 12:138","DOI":"10.3390\/biomedicines12010138"},{"key":"6132_CR97","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2159-8290.CD-23-0584","volume":"14","author":"W Sang","year":"2024","unstructured":"Sang W (2024) Receptor-interacting protein kinase 2 is an immunotherapy target in pancreatic cancer. Cancer Discov 14:326\u2013347","journal-title":"Cancer Discov"},{"key":"6132_CR98","doi-asserted-by":"crossref","unstructured":"Ringheim GE, Wampole M, Oberoi KJ (2021) Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. 12:662223","DOI":"10.3389\/fimmu.2021.662223"},{"key":"6132_CR99","doi-asserted-by":"crossref","unstructured":"Schwartz DM et al (2017) Inhibition as a therapeutic strategy for immune and inflammatory diseases. 16:843\u2013862","DOI":"10.1038\/nrd.2017.201"},{"key":"6132_CR100","doi-asserted-by":"crossref","unstructured":"Espinoza-Ch\u00e1vez RM et al (2022) Targeted protein degradation for infectious diseases: from basic biology to drug discovery. 3:32\u201345","DOI":"10.1021\/acsbiomedchemau.2c00063"},{"key":"6132_CR101","doi-asserted-by":"crossref","unstructured":"Verma RJADD (2021) Development. Exploiting ubiquitin ligases for induced target degradation as an antiviral strategy. 339\u2013357","DOI":"10.1007\/978-981-16-0267-2_13"},{"key":"6132_CR102","doi-asserted-by":"crossref","unstructured":"Powell M, Blaskovich MA, Hansford KA (2021) Targeted protein degradation: the new frontier of antimicrobial discovery? 7:2050\u20132067","DOI":"10.1021\/acsinfecdis.1c00203"},{"key":"6132_CR103","doi-asserted-by":"crossref","unstructured":"Wang C et al (2025) Engineered extracellular vesicles as nanosponges for lysosomal degradation of PCSK9. 33:471\u2013484","DOI":"10.1016\/j.ymthe.2024.11.034"},{"key":"6132_CR104","doi-asserted-by":"crossref","unstructured":"Musso G, Cassader M, Gambino RJ (2016) Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. 15:249\u2013274","DOI":"10.1038\/nrd.2015.3"},{"key":"6132_CR105","first-page":"1688","volume":"31","author":"JA Gregory","year":"2024","unstructured":"Gregory JA, Hickey CM, Chavez J, Cacace AM (2024) New therapies on the horizon: targeted protein degradation in neuroscience. J C C B 31:1688\u20131698","journal-title":"J C C B"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-026-06132-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06132-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06132-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:04:42Z","timestamp":1781532282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-026-06132-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6132"],"URL":"https:\/\/doi.org\/10.1007\/s00018-026-06132-1","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"254"}}